Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti EGFR therapy. Approval was based on Study FRESCO-2, a globally-conducted, double-blind, placebo-controlled randomized trial...
May 29, 2024: Clinical Cancer Research